$0.76 Billion Forecast for Chemotherapy-Induced Neutropenia Treatment Market by 2029, Backed by Demand and Innovation
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Milestones in the Chemotherapy-Induced Neutropenia Treatment Market’s Growth Trajectory From 2025 To 2034?
The market size for the treatment of chemotherapy-induced neutropenia has demonstrated solid growth in the past few years. It’s projected that it will expand from $0.59 billion in 2024 to reach $0.62 billion in 2025, with a compound annual growth rate (CAGR) of 5.4%. Factors contributing to past growth trends include an uptick in cancer occurrence rates, an increase in chemotherapy utilization, a larger aging population, elevated hospital admission rates due to infections, and the broadening of oncology drug development pipelines.
The market size for treatments used to combat chemotherapy-induced neutropenia is on track to experience solid expansion in the coming years, potentially growing to $0.76 billion by 2029 at a compounded annual growth rate of 5.2%. This anticipated market growth can be credited to factors such as an increase in demand for targeted therapy for neutropenia, escalating investments in oncological research and development, an intensified emphasis on outpatient care, wider utilization of biosimilars, and heightened awareness of infection prevention methods. Some significant trends that could shape the market in the projected forecast period consist of advancements in long-acting granulocyte colony-stimulating factor therapy (G-CSF), a surge in the use of combination therapies, a growing preference for home-based health care solutions, a surge in approvals for biosimilars, and the integration of digital health monitoring instruments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp
What Are the Core Growth Drivers Propelling the Chemotherapy-Induced Neutropenia Treatment Market Forward?
The escalating prevalence of cancer is predicted to fuel the expansion of the chemotherapy-induced neutropenia treatment market in the future. Cancer encompasses a range of ailments characterized by uncontrollable proliferation and spread of irregular cells in the body. The surge in cancer occurrences is attributable to the aging population, as aged individuals are at an increased risk of cancer due to accumulated genetic mutations and weakened immune function over time. Treatment for chemotherapy-induced neutropenia contributes to cancer management by lowering the risk of infections through immune support, thus enabling patients to continue with their chemotherapy sessions with lesser interruptions. This maximizes treatment efficacy by decreasing complications, thereby boosting patient safety and quality of life. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that the total number of cancer diagnoses in Australia had escalated to 160,570 in 2022, representing an increase of 3,789 cases from 156,781 in 2021. Consequently, the growing prevalence of cancer is propelling the expansion of the chemotherapy-induced neutropenia treatment market.
What Segment Types Define the Chemotherapy-Induced Neutropenia Treatment Market Structure?
The chemotherapy-induced neutropenia treatmentmarket covered in this report is segmented –
1) By Type: Antibiotic Therapy; Granulocyte Colony-Stimulating Factor Therapy (G-CSF); Granulocyte Transfusion; Other Types
2) By Route of Administration: Subcutaneous; Intravenous
3) By Indication: Solid Tumors; Hematological Malignancies; Other Indications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Specialty Clinics; Homecare Settings
Subsegments:
1) By Antibiotic Therapy: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics; Prophylactic Antibiotics
2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim; Pegfilgrastim; Lenograstim
3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion; Autologous Granulocyte Transfusion
4) By Other Types: Antifungal Therapy; Stem Cell Therapy; Immunomodulatory Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24190&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Chemotherapy-Induced Neutropenia Treatment Market?
North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theChemotherapy-Induced Neutropenia Treatment Industry Evolution?
Leading firms in the chemotherapy-induced neutropenia treatment market are striving to develop groundbreaking products and secure approvals, such as long-acting formulations that improve convenience for patients, decrease the necessity for frequent doses, and bolster compliance with treatment protocols. Long-acting formulations entail pharmaceutical compounds that gradually release active chemicals over a sustained period, thereby decreasing the need for frequent administration. For example, in December 2023, U.S. based biopharmaceutical firm, Coherus BioSciences Inc., was granted approval by the U.S. Food and Drug Administration (FDA) for their product, Udenyca Onbody, an innovative on-body injector that is ready-to-use. This gadget, equipped with a long-acting formula, delivers pegfilgrastim automatically about 27 hours post chemotherapy, eradicating the requirement for an injection the following day. Udenyca Onbody enhances the patient experience by providing timely preventative treatment for chemotherapy-induced neutropenia, while simultaneously minimizing trips to the clinic and improving treatment adherence.
View the full report here:
What Is the Definition of the Chemotherapy-Induced Neutropenia Treatment Market?
Chemotherapy-induced neutropenia treatment is medical management used to help cancer patients whose white blood cell levels drop after chemotherapy. It reduces the duration and severity of neutropenia to prevent infections. The treatment often involves growth factors and chemotherapy dose adjustments, while early intervention supports schedule adherence and enhances patient outcomes.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24190
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
